Company (Biotech)
Daiichi Sankyo: Pipeline, Products, Performance, Potential
| Publication Date | June 2008 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 96 |
| ISBN Number | not applicable |
| Product Code | ESP01090 |
Price
approximately: $901 | €664
Order above formats by FAX
Summary
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Contents
- Executive Summary
- A Detailed And Comprehensive Overview Of Current Financial Position, Company Strategy, Product And Pipeline Analysis.
- Therapeutic Area Focus
- Key Product Analysis And Forecasting
- Cardiovascular
- Artist (Carvedilol)
- Mevalotin/Pravachol (Pravastatin)
- Olmetec/Benicar (Olmesartan Medoxil)
- Plavix (Clopidogrel Sulfate)
- Welchol (Colesevelam)
- Infection
- Cravit (Levofloxacin)
- Gracevit (Sitafloxacin Hydrate)
- Bone And Joints
- Evista (Raloxifene)
- Loxonin (Loxoprofen)
- Metabolism
- Venofer
- Immunity And Allergy
- Zyrtec (Cetirizine)
- Cancer
- Topotecin (Irinotecan)
- Operational Data
- A Wealth Of Background And Detail
- A Full 5-Year Financial Performance Assessment
- Key Agreements
- Infrastructure
- Subsidiaries And Joint Ventures
